专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20230050345A1 METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY 有权
公开(公告)号：US20230050345A1
公开(公告)日：2023-02-16
申请号：US17715218
申请日：2022-04-07
申请人： CELLECTIS
发明人： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cécile SCHIFFER-MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC分类号： A61K35/17 , C12N5/0783 , C07K16/28 , C07K14/725 , C07K14/705 , C12N15/85
摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

32. 发明申请

US20220233588A1 CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION 有权
公开(公告)号：US20220233588A1
公开(公告)日：2022-07-28
申请号：US16625678
申请日：2018-07-02
申请人： CELLECTIS
发明人： David SOURDIVE , Aymeric DUCLERT , Mathieu SIMON , Philippe DUCHATEAU , Alan Marc WILLIAMS , Laurent POIROT
IPC分类号： A61K35/17 , C12Q1/6881
摘要： The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

33. 发明申请

US20220177914A1 USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS 有权
公开(公告)号：US20220177914A1
公开(公告)日：2022-06-09
申请号：US17674436
申请日：2022-02-17
申请人： Cellectis
发明人： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC分类号： C12N15/85 , A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
摘要： A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

34. 发明申请

US20200277625A1 METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM 审中-公开
公开(公告)号：US20200277625A1
公开(公告)日：2020-09-03
申请号：US16793896
申请日：2020-02-18
申请人： Cellectis
发明人： Philippe DUCHATEAU , André CHOULIKA , Laurent POIROT
IPC分类号： C12N15/85 , A61K35/17 , C12N5/0783 , C12N9/22 , C12N15/90
摘要： The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

35. 发明申请

US20200224163A1 TARGETED GENE INSERTION FOR IMPROVED IMMUNE CELLS THERAPY 审中-公开
公开(公告)号：US20200224163A1
公开(公告)日：2020-07-16
申请号：US16340222
申请日：2017-10-19
申请人： CELLECTIS
发明人： Brian BUSSER , Philippe DUCHATEAU , Alexandre JUILLERAT , Laurent POIROT , Julien VALTON
IPC分类号： C12N5/0783 , A61K35/17 , C12N15/90 , C12N9/22
摘要： The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

36. 发明申请

US20190216853A1 USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS 审中-公开
公开(公告)号：US20190216853A1
公开(公告)日：2019-07-18
申请号：US16361370
申请日：2019-03-22
申请人： Cellectis
发明人： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC分类号： A61K35/17 , C07K14/705 , C12N5/0783 , C07K14/725 , C07K16/28
摘要： A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

37. 发明申请

US20180044399A1 INHIBITORY CHIMERIC ANTIGEN RECEPTORS 审中-公开
公开(公告)号：US20180044399A1
公开(公告)日：2018-02-15
申请号：US15525906
申请日：2015-11-09
申请人： RINAT NEUROSCIENCE CORP. , CELLECTIS
发明人： Arvind RAJPAL , Shobha Chowdary POTLURI , Laurent POIROT , Alexandre JUILLERAT , Thomas Charles PERTEL , Donna Marie STONE , Barbra Johnson SASU
IPC分类号： C07K14/705 , C07K14/725 , A61K35/17 , C07K16/28 , C12N5/0783
CPC分类号： C07K14/70503 , A61K35/17 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/3069 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N2510/00
摘要： The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or

38. 发明申请

US20170360835A1 USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS 审中-公开
公开(公告)号：US20170360835A1
公开(公告)日：2017-12-21
申请号：US15659792
申请日：2017-07-26
申请人： Cellectis
发明人： Roman GALETTO , Agnes GOUBLE , Stephanie GROSSE , Cecile MANNIOUI , Laurent POIROT , Andrew SCHARENBERG , Julianne SMITH
IPC分类号： A61K35/17 , C07K16/28 , C12N5/0783 , C07K14/725 , C07K14/705 , A61K38/00
CPC分类号： A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
摘要： A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

39. 发明申请

US20170035866A1 METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENT 审中-公开
标题翻译：用于产生抗ARGININE和/或TRYPTOPHAN DEPLETED MICROENVIRONMENT的免疫细胞的方法
公开(公告)号：US20170035866A1
公开(公告)日：2017-02-09
申请号：US15302913
申请日：2015-04-10
申请人： CELLECTIS
发明人： Laurent POIROT , Mathieu SIMON
IPC分类号： A61K39/00 , C07K14/725 , C12N9/12
摘要： The present invention pertains to engineered immune cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immune cells of the present invention are characterized in that at least one gene selected from a gene encoding GCN2 and a gene encoding PRDM1 is inactivated or repressed. Such modified Immune cells are resistant to an arginine and/or tryptophan depleted microenvironment caused by, e.g., tumor cells, which makes the immune cells of the invention particularly suitable for immunotherapy. The invention opens the way to standard and affordable adoptive immunotherapy strategies using immune cells for treating different types of malignancies.
摘要翻译：本发明涉及工程改造的免疫细胞，其制备方法及其用作药物，特别是用于免疫治疗。本发明的工程化免疫细胞的特征在于，选自编码GCN2的基因和编码PRDM1的基因的至少一种基因被灭活或抑制。这种修饰的免疫细胞对由例如肿瘤细胞引起的精氨酸和/或色氨酸消耗的微环境具有抗性，这使得本发明的免疫细胞特别适用于免疫治疗。本发明开启了使用免疫细胞治疗不同类型恶性肿瘤的标准和负担得起的过继免疫治疗策略的方法。

40. 发明申请

US20160272999A1 METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM 有权
标题翻译：通过使用RNA指导的CAS核酸系统来工程化免疫球蛋白的方法
公开(公告)号：US20160272999A1
公开(公告)日：2016-09-22
申请号：US14892934
申请日：2014-04-01
申请人： CELLECTIS
发明人： Philippe DUCHATEAU , André CHOULIKA , Laurent POIROT
IPC分类号： C12N15/85
CPC分类号： C12N15/85 , C12N5/0636 , C12N5/0637 , C12N5/0638 , C12N9/22 , C12N2510/00
摘要： The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
摘要翻译：本发明涉及开发用于免疫治疗的遗传工程化，优选非同种异体反应性T细胞的方法。该方法涉及使用RNA引导的核酸内切酶，特别是Cas9 / CRISPR系统，以特异性靶向T细胞中关键基因的选择。工程化T细胞还旨在表达嵌合抗原受体（CAR）以将其免疫活性重定向于恶性或感染细胞。本发明开启了使用T细胞治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式